Dummer Reinhard, Foss Francine, Dreno Brigitte, Bagot Martine
Department of Dermatology, University Hospital of Zurich, Switzerland.
Semin Oncol. 2006 Feb;33(1 Suppl 3):S26-32. doi: 10.1053/j.seminoncol.2005.12.020.
There are now a wide variety of therapeutic options for managing patients with cutaneous T-cell lymphoma-related symptoms. These include skin-directed therapies such as psoralen with UVA irradiation (PUVA), topical chemotherapies such as mechlorethamine (nitrogen mustard) and carmustine (BCNU), electron beam radiation, and systemic therapies such as chemotherapy, photopheresis, and interferons. Although treatment algorithms exist for patients with early stage disease, often treatments are individualized, based on patient specific factors, cost, and accessibility of referral centers for specialized therapies. This article provides details of five real-life case studies to illustrate how cutaneous T-cell lymphoma management can be tailored to the needs of each individual patient.
